Novel Applications of Anti-CD25 Antibody-Maytansine Conjugates
Legal Citation
Summary of the Inventive Concept
Expanding the therapeutic potential of anti-CD25 antibody-maytansine conjugates to novel applications in neurological disorders, cancer treatment, and diagnostic detection of CD25 expression
Background and Problem Solved
The original patent disclosed anti-CD25 antibody-maytansine conjugates for treating certain diseases, but its scope was limited to specific therapeutic areas. This inventive concept addresses the need for exploring new applications of this core technology to tackle unmet medical needs in diverse fields
Detailed Description of the Inventive Concept
The newly generated claims describe novel applications of anti-CD25 antibody-maytansine conjugates, including treating neurological disorders, preventing neuroinflammation, targeting CD25-expressing cancer cells, delivering conjugates through microfluidic devices, and detecting CD25 expression in cells. These applications leverage the conjugate's ability to modulate CD25 expression, reducing inflammation and promoting targeted therapy
Novelty and Inventive Step
The inventive concept's novelty lies in its expansion of the conjugate's therapeutic scope to previously unexplored areas, such as neurological disorders and diagnostic detection. The inventive step involves recognizing the potential of the core technology to address unmet needs in these fields and adapting it to these new applications
Alternative Embodiments and Variations
Alternative embodiments may include varying the maytansinoid structure, modifying the antibody's isotype or affinity, or using different conjugation chemistries. Variations could also involve combining the conjugate with other therapeutic agents or using it in conjunction with gene editing technologies
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in the pharmaceutical and biotechnology industries, with potential applications in neurological disorders, cancer treatment, and diagnostic detection. The market for these applications is substantial, with growing demand for targeted and effective therapies
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K47/6807 |
| C | C07 | C07K16/2866 |
| A | A61 | A61K47/65 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Biomedical engineering and pharmaceutical chemistry, specifically protein-small molecule therapeutic conjugates, antibody-drug conjugates, and targeted cellular therapies with a focus on CD25-targeted immunomodulatory treatments
Person of Ordinary Skill (PHOSITA) Profile
A skilled practitioner with advanced degrees in biochemistry, molecular biology, or pharmaceutical sciences, possessing expertise in antibody engineering, conjugation chemistry, and therapeutic targeting strategies, with knowledge of immunology and drug delivery mechanisms
Obviousness Rationale
A person of ordinary skill would recognize the inherent potential of anti-CD25 antibody-maytansine conjugates to be adaptable across multiple therapeutic domains based on the fundamental mechanism of CD25 targeting and the modular nature of antibody-drug conjugate technologies. The source patent establishes a core technological platform that a skilled practitioner would naturally explore for expanded applications in neurological disorders, cancer treatment, and diagnostic detection. These variations represent predictable extensions of the original conjugate technology using standard biomedical engineering techniques.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,637 |
|---|---|
| Title | Anti-CD25 antibody-maytansine conjugates and methods of use thereof |
| Assignee(s) | R.P. Scherer Technologies, LLC |